Literature DB >> 31802034

Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway.

Chao Liu1,2, Zhaoying Yao1,2, Jianing Wang3, Wen Zhang1,2, Yan Yang4, Yan Zhang5, Xinliang Qu6, Yubing Zhu1,2, Jianjun Zou1,2, Sishi Peng2,7, Yan Zhao1,2, Shuli Zhao7, Bangshun He7, Qiongyu Mi7, Xiuting Liu8, Xu Zhang9,10,11, Qianming Du12.   

Abstract

Infiltrated macrophages are an important constituent of the tumor microenvironment and play roles in tumor initiation and progression by promoting immune evasion. However, the molecular mechanism by which macrophage-derived cytokines foster immune escape of colorectal cancer (CRC) is unclear. Here, we demonstrated that macrophage infiltration induced by lipopolysaccharide (LPS) or a high-cholesterol diet (HCD) significantly promoted CRC growth. Similarly, LPS and poly (I:C) remarkably increased the volume of CT26 cell allograft tumors. C-C motif chemokine ligand 5 (CCL5), which is secreted by macrophages, inhibited T-cell-mediated killing of HT29 cells and promoted immune escape by stabilizing PD-L1 in vitro and in vivo. Mechanistically, CCL5 resulted in formation of nuclear factor kappa-B p65/STAT3 complexes, which bound to the COP9 signalosome 5 (CSN5) promoter, leading to its upregulation. Moreover, CSN5 modulated the deubiquitination and stability of PD-L1. High expression of CSN5 in CRC was associated with significantly shorter survival. Furthermore, compound-15 was identified as an inhibitor of CSN5, and destabilized PD-L1 to alleviate the tumor burden. Our results suggest that the novel CCL5-p65/STAT3-CSN5-PD-L1 signaling axis is significantly activated by LPS or HCD-driven macrophage infiltration in an animal model of CRC, which likely has therapeutic and prognostic implications for human cancers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31802034      PMCID: PMC7244707          DOI: 10.1038/s41418-019-0460-0

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  40 in total

1.  Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome.

Authors:  Rati Verma; L Aravind; Robert Oania; W Hayes McDonald; John R Yates; Eugene V Koonin; Raymond J Deshaies
Journal:  Science       Date:  2002-08-15       Impact factor: 47.728

Review 2.  The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer.

Authors:  Jiajing Cai; Qi Qi; Xuemeng Qian; Jia Han; Xinfang Zhu; Qi Zhang; Rong Xia
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-08       Impact factor: 4.553

Review 3.  A genomic and functional inventory of deubiquitinating enzymes.

Authors:  Sebastian M B Nijman; Mark P A Luna-Vargas; Arno Velds; Thijn R Brummelkamp; Annette M G Dirac; Titia K Sixma; René Bernards
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

Review 4.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

5.  Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas.

Authors:  Jie Chen; Guosheng Li; Hong Meng; Yuchen Fan; Yonghong Song; Shurong Wang; Faliang Zhu; Chun Guo; Lining Zhang; Yongyu Shi
Journal:  Cancer Immunol Immunother       Date:  2011-08-19       Impact factor: 6.968

Review 6.  Macrophages associated with tumors as potential targets and therapeutic intermediates.

Authors:  Serguei Vinogradov; Galya Warren; Xin Wei
Journal:  Nanomedicine (Lond)       Date:  2014-04       Impact factor: 5.307

7.  Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

Authors:  Qiong-wen Zhang; Lei Liu; Chang-yang Gong; Hua-shan Shi; Yun-hui Zeng; Xiao-ze Wang; Yu-wei Zhao; Yu-quan Wei
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

Review 8.  The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.

Authors:  L Bingle; N J Brown; Claire E Lewis
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

9.  JAMM: a metalloprotease-like zinc site in the proteasome and signalosome.

Authors:  Xavier I Ambroggio; Douglas C Rees; Raymond J Deshaies
Journal:  PLoS Biol       Date:  2003-11-24       Impact factor: 8.029

10.  CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer.

Authors:  Shengbo Zhang; Ming Zhong; Chao Wang; Yanjie Xu; Wei-Qiang Gao; Yan Zhang
Journal:  Cell Death Dis       Date:  2018-07-10       Impact factor: 8.469

View more
  35 in total

1.  ZIM3 activation of CCL25 expression in pulmonary metastatic nodules of osteosarcoma recruits M2 macrophages to promote metastatic growth.

Authors:  Jing Li; Chenguang Zhao; Dong Wang; Shuang Wang; Hui Dong; Difan Wang; Yubing Yang; Jiaxi Li; Feng Cui; Xijing He; Jie Qin
Journal:  Cancer Immunol Immunother       Date:  2022-09-26       Impact factor: 6.630

2.  IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.

Authors:  Jiefei Zhu; Yan Li; Xu Lv
Journal:  Immunogenetics       Date:  2022-09-03       Impact factor: 3.330

3.  Intramyocardial injected human umbilical cord-derived mesenchymal stem cells (HucMSCs) contribute to the recovery of cardiac function and the migration of CD4+ T cells into the infarcted heart via CCL5/CCR5 signaling.

Authors:  Jing Liu; Xiaoting Liang; Mimi Li; Fang Lin; Xiaoxue Ma; Yuanfeng Xin; Qingshu Meng; Rulin Zhuang; Qingliu Zhang; Wei Han; Ling Gao; Zhiying He; Xiaohui Zhou; Zhongmin Liu
Journal:  Stem Cell Res Ther       Date:  2022-06-11       Impact factor: 8.079

4.  Inhaled or Ingested, Which Is Worse, E-Vaping or High-Fat Diet?

Authors:  Hui Chen; Yik Lung Chan; Andrew E Thorpe; Carol A Pollock; Sonia Saad; Brian G Oliver
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 5.  The nuclear transportation of PD-L1 and the function in tumor immunity and progression.

Authors:  Liyan Qu; Jiakang Jin; Jianan Lou; Chao Qian; Jinti Lin; Ankai Xu; Bing Liu; Man Zhang; Huimin Tao; Wei Yu
Journal:  Cancer Immunol Immunother       Date:  2022-03-05       Impact factor: 6.630

6.  Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells.

Authors:  Mio Yamaguchi; Kiyoshi Takagi; Koki Narita; Yasuhiro Miki; Yoshiaki Onodera; Minoru Miyashita; Hironobu Sasano; Takashi Suzuki
Journal:  Int J Mol Sci       Date:  2021-02-15       Impact factor: 5.923

7.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.

Authors:  Yu Wang; Qingguo Sun; Ning Mu; Xiaoyang Sun; Yingying Wang; Songqing Fan; Ling Su; Xiangguo Liu
Journal:  Cell Commun Signal       Date:  2020-07-14       Impact factor: 5.712

Review 8.  Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.

Authors:  Xiaoli Hu; Jing Wang; Man Chu; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

Review 9.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 10.  NF-κB and Its Role in Checkpoint Control.

Authors:  Annika C Betzler; Marie-Nicole Theodoraki; Patrick J Schuler; Johannes Döscher; Simon Laban; Thomas K Hoffmann; Cornelia Brunner
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.